Press release: Safety, pharmacokinetics, and pharmacodynamics of CT-996, an oral small-molecule, signal-biased GLP-1 receptor agonist over 4 weeks in adults with obesity
Administration Options Subcutaneous Injections (most effective, daily or weekly) Oral Capsules (limited efficacy, for certain peptides) Nasal Sprays (used for cognitive/hormonal focus) Topical Creams (skin regeneration) Follow-Up & Adjustments We monitor your response and progress over the course of your therapyadjusting dosage, combining peptides, or integrating with other services like IV therapy, HRT, or functional nutrition
The maximum blockade achievable was estimated to be around 320%, and half of this effect could be achieved with a dose of approximately 0.25 mg TE and a specific blood concentration of 4 ng/ml
This distinction protects patients from contamination risks during preparation